Previous close | 68.50 |
Open | 68.50 |
Bid | 68.00 x 60000 |
Ask | 68.50 x 60000 |
Day's range | 68.00 - 68.50 |
52-week range | 45.51 - 70.00 |
Volume | |
Avg. volume | 79 |
Market cap | 100.989B |
Beta (5Y monthly) | 0.77 |
PE ratio (TTM) | 62.39 |
EPS (TTM) | 1.09 |
Earnings date | 25 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP). As components of the mCRM System, the devices are designed to work together wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therap
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.